MedWatch

FDA awards priority review to Genmab and Abbvie's cancer candidate

Potential cancer treatment epcoritamab will now be reviewed under the US Food and Drug Administration’s accelerated pathway.

Photo: Joost Melis / Genmab / PR

The road to market ahead of Genmab’s cancer candidate, epcoritamab, has just gotten shorter after the US Food and Drug Administration, FDA, has decided to accelerate review, a company press release announces.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs